Wells Fargo’s Iterum Therapeutics ITRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-85
| Closed | -$3 | – | 7451 |
|
|
2026
Q1 | $3 | Hold |
85
| – | – | ﹤0.01% | 7069 |
|
|
2025
Q4 | $28 | Hold |
85
| – | – | ﹤0.01% | 6655 |
|
|
2025
Q3 | $57 | Hold |
85
| – | – | ﹤0.01% | 6474 |
|
|
2025
Q2 | $85 | Hold |
85
| – | – | ﹤0.01% | 6497 |
|
|
2025
Q1 | $105 | Hold |
85
| – | – | ﹤0.01% | 6371 |
|
|
2024
Q4 | $150 | Hold |
85
| – | – | ﹤0.01% | 6387 |
|
|
2024
Q3 | $93 | Sell |
85
-1,200
| -93% | -$1.43K | ﹤0.01% | 6287 |
|
|
2024
Q2 | $1.47K | Hold |
1,285
| – | – | ﹤0.01% | 6060 |
|
|
2024
Q1 | $1.98K | Hold |
1,285
| – | – | ﹤0.01% | 6036 |
|
|
2023
Q4 | $2.53K | Hold |
1,285
| – | – | ﹤0.01% | 6063 |
|
|
2023
Q3 | $1.03K | Buy |
1,285
+1,200
| +1,412% | +$1.14K | ﹤0.01% | 6195 |
|
|
2023
Q2 | $91 | Hold |
85
| – | – | ﹤0.01% | 6892 |
|
|
2023
Q1 | $85 | Hold |
85
| – | – | ﹤0.01% | 6968 |
|
|
2022
Q4 | $71 | Sell |
85
-220
| -72% | -$313 | ﹤0.01% | 6895 |
|
|
2022
Q3 | $0 | Sell |
305
-1
| -0.3% | -$3 | ﹤0.01% | 6999 |
|
|
2022
Q2 | $1K | Hold |
306
| – | – | ﹤0.01% | 6531 |
|
|
2022
Q1 | $2K | Hold |
306
| – | – | ﹤0.01% | 6675 |
|
|
2021
Q4 | $2K | Sell |
306
-600
| -66% | -$4.63K | ﹤0.01% | 6886 |
|
|
2021
Q3 | $8K | Hold |
906
| – | – | ﹤0.01% | 6271 |
|
|
2021
Q2 | $31K | Hold |
906
| – | – | ﹤0.01% | 5746 |
|
|
2021
Q1 | $19K | Buy |
906
+406
| +81% | +$9.66K | ﹤0.01% | 6167 |
|
|
2020
Q4 | $7K | Buy |
+500
| New | +$5.85K | ﹤0.01% | 6089 |
|
Other funds holding ITRM
Wells Fargo's ITRM Position: Q2 2026 in Review
Wells Fargo sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 85 shares — an estimated $3 sold.
Wells Fargo first reported a position in ITRM in Q4 2020 and held it in 22 quarters. The position peaked at $31K in Q2 2021. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.
- Wells Fargo reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
- Wells Fargo sold 85 Iterum Therapeutics shares in Q2 2026, an estimated $3.
- Wells Fargo first reported a position in Iterum Therapeutics in Q4 2020 and held it in 22 quarters.
- Wells Fargo's Iterum Therapeutics position peaked at $31K in Q2 2021.
- 2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.